Since December, public offerings have been intensively investigated, and these pharmaceutical and biological companies have been targeted

 2021 is about to end, and it is reported that intensive public fundraising research welcomes the new year
.
According to statistics, since December, the agency has investigated a total of 417 A-share listed companies
.
Among them, the fund company investigated 308 A-share listed companies, covering various fields such as machinery and equipment, biomedicine, and electronics
.
It is reported that in the field of medical biology, Haier Biotechnology, New Industries, and International Medicine have welcomed more than 40 fund companies to investigate
.
Since December, public offerings have been intensively investigated, and pharmaceutical and biological companies have been targeted (picture source: Pharmaceutical Network) Haier Biological has been investigated by 71 fund companies Since December, Haier Biological has been investigated by 286 institutions, of which 71 fund companies have been investigated
.
Since December, its stock price has fallen by 2.
65%
.
According to reports, in the investigation, in view of the company’s R&D advantages, Haier Biotechnology stated that the company has deep R&D experience and technology accumulation in the field of cryogenic storage, has broken through a number of key technologies, built high technical barriers, and led or participated in drafting 17 national, industry, and group standards and technical specifications
.
The company has set up an open innovation system of "site→lab→market", and solves customer pain points through continuous interaction with customers
.
Through continuous R&D and innovation, the company has successively made breakthroughs in a number of core technologies such as integration of the Internet of Things, automation, microbial cultivation, and environmental simulation to achieve the layout and development of multiple types of biosafety products
.
New industries are investigated by 47 fund companies Since December, new industries have been investigated by 173 institutions, of which 47 fund companies have investigated
.
Since December, its stock price has fallen 6.
98%
.
It is understood that the main business of the new industry is the research and development, production, sales and service of in vitro diagnostic products.
The company’s products are mainly used to provide disease prevention, diagnosis, treatment monitoring, prognosis observation, health status evaluation, and diagnostic information for genetic disease prediction
.
It replied in the Investor Relations Activity Record Form released on December 10 that 14 reagent projects including the company’s tumor markers and thyroid were shortlisted for "Anhui Collective" to participate in the bargaining, and all negotiations were successful.

.
At the same time, 8 reagent projects including the five hepatitis B and BNP that were not shortlisted for negotiation have successfully completed the linkage price reduction
.
Therefore, the company's existing 22 reagent projects can continue to be sold in Anhui Province
.
New Industry is a company that uses "nano-immunomagnetic beads" as the key separation material of the system.
It is also a company that applies direct chemiluminescence immunoassay technology and realizes mass production of fully automated chemiluminescence immunoassay instruments and supporting reagents
.
International medicine is investigated by 41 fund companies Since December, the new industry has been investigated by 179 institutions, of which 41 fund companies have been investigated
.
Since December, its stock price has risen 8.
19%
.
According to the research announcement, when researching international medicine, the organization pays more attention to the operation of its hospitals and the progress of the innovation sector
.
In recent years, International Medicine has increased its profitability by expanding hospital beds and increasing patient visits
.
At present, the company's newly opened hospital is still in the "climbing" stage.
It remains to be seen whether it can help it turn losses into profits in the future, which in turn will affect the stock price
.
The business structure of International Medicine is "one group + three hospitals"
.
The three major hospitals refer to the Central Hospital, High-tech Hospital, Shangluo Hospital and other institutions
.
The central hospital is the new engine of international medical performance
.
At the recent roadshow, the company disclosed its operating conditions to the organization
.
In the first three quarters of this year, the operating income of the central hospital increased by 158% year-on-year to 1.
137 billion yuan, accounting for 55.
5% of the international medical income in the same period
.
Analysts pointed out that the factors affecting the international medical valuation: on the one hand, the profitability of the three major hospitals, on the other hand, the imagination of the innovation sector
.
Data show that as of December 16 this year, the total market value of international medicine reached 27 billion yuan
.